Contents

Disclaimer

Oxford University Press makes no representation, express or implied, that the drug dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most up to date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations. The authors and the publishers do not accept responsibility or legal liability for any errors in the text or for the misuse or misapplication of material in this work. Except where otherwise stated, drug dosages and recommendations are for the non-pregnant adult who is not breastfeeding.

Show Summary Details
Page of

Pharmacotherapy of bipolar disorder: impact on neurocognition 

Pharmacotherapy of bipolar disorder: impact on neurocognition
Chapter:
Pharmacotherapy of bipolar disorder: impact on neurocognition
Author(s):

Vicent Balanzá-Martínez

, Sofia Brissos

, Maria Lacruz

, and Rafael Tabarés-Seisdedos

DOI:
10.1093/med/9780198748625.003.0025
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 23 August 2019

Neurocognitive dysfunction is a core feature of bipolar disorder (BD), which may be further compounded by several clinical factors, such as medications. There is growing interest on the potential impact of pharmacotherapy (lithium, anticonvulsants, antipsychotics, and other) on neurocognition. This chapter summarizes a critical, descriptive update of the literature, mostly focused on human data. Based on current studies, medication-associated neurocognitive side effects cannot be clearly distinguished from those intrinsic to BD. Moreover, available research is limited by several methodological flaws. We suggest some likely profitable directions to move the field forward, as well as several recommendations to manage cognitive deficits in clinical practice. The neurocognitive impact of medications used to treat BD clearly warrants further, higher-quality research.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.